Tantucci C, Santeusanio F, Beschi M, Castellano M, Sorbini C, Grassi V
CNR Respiratory Unit, University of Perugia, Italy.
J Endocrinol Invest. 1988 Apr;11(4):279-87. doi: 10.1007/BF03350152.
The changes of blood glucose, serum potassium (K+), plasma non-esterified fatty acids (NEFA), plasma insulin and plasma renin activity (PRA) following the preferential stimulation of beta-1 and beta-2 adrenoceptors were studied in 7 healthy subjects during a 60-min infusion of prenalterol, a new, relatively beta-1 selective agonist and salbutamol, a well known, relatively beta-2 selective agonist. Two different high and low doses were used for both agents: 300 micrograms and 600 micrograms and 1 mg and 2 mg for salbutamol and prenalterol, respectively. The levels of PRA seemed equally increased by the two agents in proportion to the dose infused, thus suggesting an equally important role for beta-1 and beta-2 adrenoceptors in renin release. Blood glucose did not change during prenalterol infusions, while increased by 12 +/- 2 mg/100 ml (mean +/- SE; p less than 0.01) and 25 +/- 3 mg/100 ml (p less than 0.01) on salbutamol, at low and high dose, respectively. Similarly the decrement of serum K+ was significantly more pronounced (p less than 0.01) after salbutamol infusion (0.6 +/- 0.07 mEq/L and 1.0 less than 0.09 mEq/L, at low and high dose, respectively) than after prenalterol (0.1 +/- 0.07 mEq/L and 0.3 +/- 0.05 mEq/L). These metabolic effects should suggest a main beta-2 adrenoceptor involvement.(ABSTRACT TRUNCATED AT 250 WORDS)
在7名健康受试者中,于60分钟输注新型相对β1选择性激动剂普瑞特罗和知名相对β2选择性激动剂沙丁胺醇期间,研究了优先刺激β1和β2肾上腺素能受体后血糖、血清钾(K+)、血浆非酯化脂肪酸(NEFA)、血浆胰岛素和血浆肾素活性(PRA)的变化。两种药物均使用了两种不同的高剂量和低剂量:沙丁胺醇分别为300微克和600微克,普瑞特罗分别为1毫克和2毫克。两种药物使PRA水平随输注剂量成比例增加,表明β1和β2肾上腺素能受体在肾素释放中起同等重要作用。输注普瑞特罗期间血糖未变化,而输注低剂量和高剂量沙丁胺醇后血糖分别升高12±2毫克/100毫升(均值±标准误;p<0.01)和25±3毫克/100毫升(p<0.01)。同样,输注沙丁胺醇后血清K+的降低(低剂量和高剂量时分别为0.6±0.07毫当量/升和1.0<0.09毫当量/升)比输注普瑞特罗后(0.1±0.07毫当量/升和0.3±0.05毫当量/升)明显更显著(p<0.01)。这些代谢效应表明主要涉及β2肾上腺素能受体。(摘要截短于250字)